Table 2.

Comparative clinico-pathological characteristics and risk group assignments in the study cohort between clinical based characterisation (DRE + systematic sampling only) versus MRI based characterisation (MRI staging and combined MRI targeted and systematic sampling) in MRI-prebiopsy cohort. *no T4 cases in this cohort, see methods for how stage was assigned for clinical and MRI assignment. European Association of Urology (EAU), American Urological Association, Cambridge Prognostic Group (CPG)

	Clinical stage and systematic biopsies		MRI stage and target systematic biopsies		Comparison
	n	Percentage (%)	n	Percentage (%)	(%)
Stage *
T1-T2	263	71.1	234	63.2	-7.8
T3	107	28.9	136	36.8	7.8
Grade Group
1	101	27.3	96	25.9	-1.4
2	123	33.2	133	35.9	2.7
3	60	16.2	63	17.0	0.8
4	13	3.5	17	4.6	1.1
5	57	15.4	61	16.5	1.1
Benign	16	4.3	-	-	-4.3
EAU (Cancers only)	(n = 354)		(n = 370)
Low risk	67	18.9	66	17.8	-1.1
Intermediate risk	155	43.8	143	38.7	-5.1
High	132	37.3	161	43.5	6.2
AUA (Cancers only)
Low risk	67	18.9	66	17.8	-1.1
Favourable intermediate risk	86	24.3	78	21.1	-3.2
Unfavourable intermediate risk	69	19.5	65	17.6	-1.9
High risk	132	37.3	161	43.5	6.2
CPG (Cancers only)
1	67	18.9	66	17.8	-1.1
2	86	24.3	78	21.1	-3.2
3	69	19.5	65	17.6	-1.9
4	64	18.1	83	22.4	4.3
5	68	19.2	78	21.1	1.9